- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06087887
Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
October 11, 2023 updated by: Zhe Fan
The goal of this observational study is to learn about in small bowel adenocarcinoma patients.
The main question it aims to answer is the association between tumor size and prognosis in patients with small bowel adenocarcinoma.
Participants will be compared for the relationship between tumor size and prognosis.
Study Overview
Study Type
Observational
Enrollment (Actual)
8163
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Liaoning
-
Dalian, Liaoning, China
- Dalian Third People's Hospital Affiliated to Dalian Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Data of Small Bowel adenocarcinoma patients from 2004 to 2019 was collected from the SEER database using the SEER*Stat software (version 8.4.0.1).
Description
Inclusion Criteria:
- pathology confirmed as SBA;
- received surgery and complete postoperative follow-up data;
- histology type code 8140-8380.
Exclusion Criteria:
Cases with unknown tumor location, size, TNM staging, race, and degree of differentiation were excluded. Finally, 8,163 eligible patients were included in the analysis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
tumor size 0-1cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 0-1 cm.
|
no interventions
|
tumor size 1-2 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 1-2 cm.
|
|
tumor size 2-3 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 2-3 cm.
|
|
tumor size 3-4 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 3-4 cm.
|
|
tumor size 4-5 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 4-5 cm.
|
|
tumor size 5-6 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 5-6 cm.
|
|
tumor size 6-7 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 6-7 cm.
|
|
tumor size 7-8 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 7-8 cm.
|
|
tumor size 8-9 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 8-9 cm.
|
|
tumor size 9-10 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of 9-10 cm.
|
|
tumor size >10 cm
No intervention.
Select small bowel adenocarcinoma patients with tumor size of >10 cm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
Time Frame: 2024.9.1
|
We will study the relationship between tumor size and prognosis in small bowel adenocarcinoma patients in the SEER database
|
2024.9.1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Actual)
September 1, 2023
Study Completion (Actual)
October 1, 2023
Study Registration Dates
First Submitted
October 11, 2023
First Submitted That Met QC Criteria
October 11, 2023
First Posted (Actual)
October 18, 2023
Study Record Updates
Last Update Posted (Actual)
October 18, 2023
Last Update Submitted That Met QC Criteria
October 11, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ThirdPHDalian
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prognosis
-
Assistance Publique Hopitaux De MarseilleRecruitingCardiovascular PrognosisFrance
-
University Hospital of FerraraCompletedStents | PrognosisItaly, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedKidney Transplantation | Kidney Transplant Rejection | Prognosis | Risk StratificationFrance, Germany, Spain, Switzerland
-
Universidad Autonoma de San Luis PotosíUnknownCalcium , Prognosis in PatientsMexico
-
LiuJunFengOrigiMedUnknownPrognosis of Patients With ESCCChina
-
Radboud University Medical CenterUnknownUnexplained Subfertile Couples With a Good Prognosis.Netherlands
-
Jingyuan,XuUnknownEvaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDSChina
-
University of California, IrvineWithdrawnCORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTUnited States
-
Zonguldak Bulent Ecevit UniversityCompletedCritical Illness | Nurse's Role | Prognosis | Risk FactorTurkey
-
Centre Hospitalier Universitaire, AmiensRecruitingDisruptive Mood Dysregulation Disorder | Prognosis Factors | Suicidal Behaviors | ActigraphyFrance
Clinical Trials on no interventions
-
RenJi HospitalNot yet recruitingConstruction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer (CRGGCext)Biliary Tract Diseases | Gallbladder Neoplasms | Gallbladder Cancer
-
Peking UniversityNational Natural Science Foundation of ChinaNot yet recruitingObesity | Anemia | Preterm Birth | Child Development | Gestational Diabetes | Mother-Infant Interaction | Gestational Hypertension | Pregnancy Outcomes | Health Problems in PregnancyChina
-
UMC UtrechtJohns Hopkins University; NYU Langone Health; University Medical Center Groningen and other collaboratorsRecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Diseases | Pancreas Adenocarcinoma | Pancreatic Cyst | Pancreas CystNetherlands
-
The Dental Hospital of Zhejiang University School...Not yet recruiting
-
RenJi HospitalNot yet recruitingBiliary Tract Diseases | Intrahepatic Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Gall Stone
-
Zhuang HongqingNot yet recruitingSpinal Tumor | Prognosis | Radiomics | Stereotactic RadiosurgeryChina
-
University of GenovaRecruiting
-
Huashan HospitalRecruiting
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Aalborg University Hospital and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Insulin Resistance | Pregnancy, High Risk | Overweight and Obesity | Insulin Sensitivity | Gestational Diabetes | Pregnancy in DiabeticDenmark
-
Second Affiliated Hospital, School of Medicine,...Recruiting